Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® Antibiotics specialty page provides antibiotics-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


MDR Infections: Overview of Antimicrobial Stewardships
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; Debra Goff, PharmD, FCCP; and Sandy J. Estrada Lopez, PharmD, BCPS (AQID), outline the function of antimicrobial stewardships regarding multidrug-resistant bacterial infections and emphasize the importance of personnel at all levels within this system.
<i>Pseudomonas</i> Infections: Nuancing the Use of Antibiotics
Marin Hristos Kollef, MD; Peter L. Salgo, MD; Andrew Shorr, MD; and Yoav Golan, MD, share insight on the appropriate approach to using antibiotics when treating pseudomonas infections at multiple levels of care.
Understanding Gram-Positive Nosocomial Infections
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; Debra Goff, PharmD, FCCP; Andrew Shorr, MD; and Sandy J. Estrada Lopez, PharmD, BCPS (AQID), give considerations for gram-positive nosocomial infections, including how to identify risk and the prevalence of methicillin-resistant Staphylococcus aureus in this setting.
What's the Strongest Approach for Treating <i>Pseudomonas</i> Infections?
Marin H. Kollef, MD, discusses the strongest approach for treating Pseudomonas infections.
Gram-Negative NIs: Vabomere and the TANGO II Study
Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; and Andrew Shorr, MD, discuss the recent approval of Vabomere, a combination of meropenem and vaborbactam, in the setting of gram-negative nosocomial infections based on the positive study results of the TANGO II trial.
<i>Pseudomonas</i> Infections in the ICU: Who's Susceptible?
Peter L. Salgo, MD; Marin Hristos Kollef, MD; Jason Pogue, PharmD, BCPS-AQID; Yoav Golan, MD; and Andrew Shorr, MD, identify which patients are most susceptible to Pseudomonas infections and address the settings in which risk for infection is greatest.
<i>C. difficile</i> Rates in the United Kingdom
Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.
What Are the Next Steps for Ridinilazole?
Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.
Big advances in treatment can